Painful and involuntary multiple sclerosis

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 5, 2011, Pages 763-777

  Bagnato, Francesca ^a,f   Centonze, Diego ^b,c   Galgani, Simonetta ^d   Grasso, Maria Grazia ^c   Haggiag, Shalom ^d   Strano, Stefano ^e  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

dysautonomia; MS; pain; pharmacotherapy

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATROPINE; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CARBAMAZEPINE; DOPAMINE RECEPTOR STIMULATING AGENT; DULOXETINE; ESTROGEN; ETIRACETAM; FLUDROCORTISONE; GABAPENTIN; GLATIRAMER; IBUPROFEN; INDOMETACIN; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PLACEBO; PREGABALIN; PROPRANOLOL; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; THEOPHYLLINE; UNINDEXED DRUG; VARDENAFIL;

ACUTE RESPIRATORY FAILURE; ADL DISABILITY; ANXIETY DISORDER; BLADDER DYSFUNCTION; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DYSESTHESIA; DYSPAREUNIA; DYSPEPSIA; DYSPHAGIA; DYSPNEA; EARLY INTERVENTION; ENDOSCOPY; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; FEMALE SEXUAL DYSFUNCTION; HEADACHE; HEART FAILURE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; LIFESTYLE MODIFICATION; LIMB PAIN; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; ORTHOSTATIC INTOLERANCE; PAIN; PAIN ASSESSMENT; PARESTHESIA; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRURITUS; RARE DISEASE; REHABILITATION CARE; RESTLESS LEGS SYNDROME; REVIEW; RHINITIS; SEXUAL COUNSELING; SEXUAL DYSFUNCTION; SPASTICITY; SYNCOPE; THORAX PAIN; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT PLANNING; VAGINAL BURNING SENSATION; VAGINAL DRYNESS;

CARDIOVASCULAR SYSTEM; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PAIN; PREVALENCE;

EID: 79952584775     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.540239     Document Type: Review

References (122)

1. Compston A, Coles A. Multiple Sclerosis. Lancet 2008;372:1502-17
2. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005;58:840-6 (Pubitemid 41746873)
3. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-69 (Pubitemid 27493740)
4. Solaro C, Messmer Uccelli M. Pharmacological management of pain in patients with multiple sclerosis. Drugs 2010;70:1245-54
5. Hartelius L, Svensson P. Speech and swallowing symptom associated with Parkinson's disease and multiple sclerosis: a survey. Folia Phoniatr Logop 1994;46:9-17
6. Logemann JA. Dysphagia: evaluation and treatment. Folia Phoniatr Logop 1995;47:140-64
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52 (Pubitemid 14237132)
8. Tassorelli C, Bergamaschi R, Buscone S, et al. Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurol Sci 2008;29(Suppl 4):360-3
9. De Pauw A, Dejaeger E, D'hooghe B, et al. Dysphagia in multiple sclerosis. Clin Neurol Neurosurg 2002;104:345-51 (Pubitemid 34828293)
10. Abraham SS, Yun PT. Laryngopharyngeal dysmotility in multiple sclerosis. Dysphagia 2002;17:69-74 (Pubitemid 36918854)
11. Hoppers P, Holm SE. The role of fiberoptic endoscopy in Dysphagia rehabilitation. J Head Trauma Rehabil 1999;14:475-85 (Pubitemid 29503163)
12. Calcagno P, Ruoppolo G, Grasso MG, et al. Dysphagia in multiple sclerosis-Prevalence and prognostic factors. Acta Neurol Scand 2002;105:40-3 (Pubitemid 34188268)
13. Taniguchi H, Tsukada T, Ootaki S, et al. Correspondence between food consistency and suprahyoid muscle activity, tongue pressure, and bolus transit times during the oropharyngeal phase of swallowing. J Appl Physiol 2008;105:791-9
14. Thomas FJ, Wiles CM. Dysphagia and nutritional status in multiple sclerosis. J Neurol 1999;246:677-82 (Pubitemid 29417849)
15. American Speech-Language Hearing Association. National Outcomes Measurements System (NOMS): Adult Speech-Language Pathology Training Manual. American Speech-Language Hearing Association, Rockville (Maryland); 1998
16. Restivo DA, Marchese Ragona R, Patti F, et al. Botulinum toxin improves dysphagia associated with multiple sclerosis. Eur J Neurol 2010. [Epub ahead ofprint]
17. DeAngelis T, Lublin F. Multiple sclerosis: new treatment trials and emerging therapeutic targets. Curr Opin Neurol 2008;21:261-71 (Pubitemid 351653974)
18. Inagaki D, Miyaoka Y, Ashida I, et al. Influence of food properties and body position on swallowing related muscle activity amplitude. J Oral Rehabil 2009;36:176-83
19. Henze T. What is new in symptom management? Int MS J 2007;14:22-7 (Pubitemid 46917296)
20. Payne A. Nutrition and diet in the clinical management of multiple sclerosis. J Hum Nutr Diet 2001;14:349-57 (Pubitemid 33014888)
21. Prosiegel M, Schelling A, Wagner-Sonntag E. Dysphagia and multiple sclerosis. Int MS J 2004;11:22-31 (Pubitemid 38879827)
22. Giusti A, Giambuzzi M. Management of Dysphagia in patients affected by multiple sclerosis: state of the art. Neurol Sci 2008;29(Suppl 4):364-6
23. Schrag SP, Sharma R, Jaik NJ. Complications related to percutaneous endoscopicGastrostomy (PEG) tubes. A comprehensive clinical review. J Gastrointestin Liver Dis 2007;4:407-18
24. Grasso MG, Lubich S, Guidi L, et al. Cerebellar deficit and respiratory impairment: a strong association in multiple sclerosis? Acta Neurol Scand 2000;101:98-103 (Pubitemid 30051378)
25. Gosselink R, Kovacs L, Decramer M. Respiratory muscle involvement in multiple sclerosis. Eur Respir J 1999;13:449-54 (Pubitemid 29086849)
26. Fry DK, Pfalzer LA, Chokshi AR, et al. Randomized control trial of effects of a 10-week inspiratory muscle training program on measures of pulmonary function in persons with multiple sclerosis. J Neurol Phys Ther 2007;31:162-72
27. Aiello M, Rampello A, Granella F, et al. Cough efficacy is related to the disability status in patients with multiple sclerosis. Respiration 2008;76:311-16
28. Mutluay FK, Gurses HN, Saip S. Effects of multiple sclerosis on respiratory functions. Clin Rehabil 2005;19:426-32 (Pubitemid 40716421)
29. Gosselink R, Kovacs L, Ketelaer P, et al. Respiratory muscle weakness and respiratory muscle training in severely disabled multiple sclerosis patients. Arch Phys Med Rehabil 2000;81:747-51 (Pubitemid 30349717)
30. Sadovnick AD, Eisen K, Ebers GC, et al. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193-6
31. Midgard R, Albrektsen G, Riise T, et al. Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in More and Romsdal, Norway. J Neurol Neurosurg Psychiatry 1995;58:417-21
32. Hirst C, Swingler R, Compston DA, et al. Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry 2008;79:1016-21
33. Aboussouan LS. Respiratory disorders in neurologic disease. Cleve Clin J Med 2005;72:511-20
34. Chiara T, Martin AD, Davenport PW, et al. Expiratory muscle strength training in persons with multiple sclerosis having mild to moderate disability: effect on maximal expiratory pressure, pulmonary function, and maximal voluntary cough. Arch Phys Med Rehabil 2006;87:468-73
35. Olindo S, Guillon B, Helias J, et al. Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur J Neurol 2002;9:287-91 (Pubitemid 35013915)
36. Merkelbach S, Haensch CA, Hemmer B, et al. Multiple sclerosis and the autonomic nervous system J Neurol 2006;253(Suppl 1):21-5
37. Scroth WS, Tenner SM, Rappaport BA, et al. Multiple sclerosis as a cause of atrial fibrillation and electro-cardiographic changes. Arch Neurol 1992:49:422-4
38. Frontoni M, Fiorini M, Strano S, et al. Power spectrum analysis contribution to the detection of cardiovascular dysautonomia in multiple sclerosis. Acta Neurol Scand 1996;93:241-5 (Pubitemid 26155201)
39. Linden D, Diehl RR, Berlit P. Subclinical autonomic disturbances in multiple sclerosis. J Neurol 1995;242:374-8
40. Vita G, Fazio MC, Milone S, et al. Cardiovascular autonomic dysfunction in multiple sclerosis is likely related to brainstem lesions. J Neurol Sci 1993;120:82-6 (Pubitemid 24011153)
41. Anema JR, Heijenbrok MW, Faes TJ, et al. Cardiovascular autonomic function in multiple sclerosis. J Neurol Sci 1991;104:129-34
42. Flachenecker P, Wolf A, Krauser M, et al. Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance. J Neurol 1999;246:578-86 (Pubitemid 29376284)
43. Flachenecker P, Reiners K. Abnormal baroreflex responses in multiple sclerosis. Clin Auton Res 2005;15:419
44. Kanjwal K, Karabin B, Kanjwal Y, Grubb BP. Autonomic dysfunction presenting as postural orthostatic tachycardia syndrome in patients with multiple sclerosis. Int J Med Sci 2010;7:62-7
45. Marriott JJ, Miyasaki JM, Gronseth G, et al. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 2010;74:1463-70
46. Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 2001;24:979-90 (Pubitemid 33097098)
47. Linden D, Diehl RR, Berlit P. Subclinical autonomic disturbances in multiple sclerosis. J Neurol 1995;242:374-8
48. Acevedo AR, Nava C, Arriada N, et al. Cardiovascular dysfunction in multiple sclerosis. Acta Neurol Scand 2000;10:85-8 (Pubitemid 30051375)
49. Flachenecker P, Reiners K, Krauser M, et al. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression disability. Mult Scler 2001;7:327-34 (Pubitemid 33026258)
50. Saari A, Tolonen U, Paakko E, et al. Cardiovascular autonomic dysfunction correlates with brain MRI lesion load in MS. Clin Neurophysiol 2004;115:1473-8 (Pubitemid 38596735)
51. Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009): the task force for the diagnosis and management of syncope of the European Society of Cardiology (ESC). Eur Heart J 2009;30:2631-71
52. Quaglia MG, Farina A, Palmery M, et al. Chiral investigation of midodrine, a long-acting alpha-adrenergic stimulating agent. Chirality 2004;16:356-62 (Pubitemid 38833315)
53. Wright RA, Kaufman HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998;51:120-4 (Pubitemid 28345370)
54. Pathak A, Raoul V, Montastruc JL, Senard JM. Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. Eur J Clin Pharmacol 2005;61:471-4 (Pubitemid 41573508)
55. van Lieshout JJ, ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in CO in autonomic failure. Clin Auton Res 2000;10:35-42 (Pubitemid 32250284)
56. Bayorh MA, Eatman D, Wang M, et al. Indomethacin attenuates post-suspension hypotension in Sprague-Dawley rats. J Gravit Physiol 2001;8:77-83
57. Wyller VB, Thaulow E, Amlie JP. Treatment of chronic fatigue and orthostatic intolerance with propranolol. J Pediatr 2007;150:654-5 (Pubitemid 46755817)
58. Di Girolamo E, Di Iorio C, Sabatini P, et al. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999;33:1227-30
59. Zorzon M, Zivadinov R, Monti Bragadin L, et al. Sexual dysfunction in multiple sclerosis: a 2-year follow-up study. J Neurol Sci 2001;187:1-5 (Pubitemid 32611651)
60. Demirkiran M, Sarica Y, Uguz S, et al. Multiple sclerosis patients with and without sexual dysfunction: are there any differences? Mult Scler 2006;12:209-14
61. Tepavcevic DK, Kostic J, Basuroski ID, et al. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler 2008;14:1131-6
62. Zorzon M, Zivadinov R, Bosco A, et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult Scler 1999;5:418-27 (Pubitemid 30028988)
63. Nortvedt MW, Riise T, Myhr KM, et al. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 2001;7:231-5 (Pubitemid 32780693)
64. Tzorzis V, Skriapas K, Hadjigeorgiou G, et al. Sexual dysfunction in newly diagnosed multiple sclerosis women. Mult Scler 2008;14:561-3 (Pubitemid 351943873)
65. Stenager E, Stenager EN, Jensen K. Sexual function in multiple sclerosis: a 5-year follow-up study. Ital J Neurol Sci 1996;17:67-9 (Pubitemid 126765654)
66. Nortvedt MW, Riise T, Frugard, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler 2007;13:106-12 (Pubitemid 46152768)
67. Mattson D, Petrie M, Srivastava DK, et al. Multiple sclerosis. Sexual dysfunction and its response to medications. Arch Neurol 1995;52:862-8
68. Fletcher SG, Castro-Borrero W, Remington G, et al. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol 2009;6:96-107
69. Hulter BM, Lundberg PO. Sexual function in women with advanced multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:83-6
70. Zivadinov R, Zorzon M, Locatelli L, et al. Sexual dysfunction in multiple sclerosis: a MRI, neuropsychological and urodynamic study. J Neurol Sci 2003;210:73-6 (Pubitemid 36539408)
71. Janardhan V, Bakshi R Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Arch Neurol 2000;57:1485-91
72. McCabe MP. Exacerbation ofsymptoms among people with multiple sclerosis patients: impact on sexuality and relationships over time. Arch Sex Behav 2004;33:593-601 (Pubitemid 39382628)
73. Valleroy ML, Kraft GH. Sexual dysfunction in multiple sclerosis. Arch Phys Med Rehabil 1984;65:125-8 (Pubitemid 14197595)
74. Betts CD, Jones SJ, Fowler CG, et al. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain 1994;117:1303-10
75. Zivadinov R, Zorzon M, Bosco A, et al. Sexual dysfunction in multiple sclerosis: II. correlation analysis. Mult Scler 1999;5:428-31 (Pubitemid 30028989)
76. Barak Y, Achiron A, Elizur A, et al. Sexual dysfunction in relapsing-remitting multiple sclerosis: magnetic resonance imaging, clinical, and psychological correlates. J Psychiatry Neurosci 1996;21:255-8 (Pubitemid 126737066)
77. Haggiag S, Ricci G, Bolla G, et al. Gender differences in sexual dysfunction among a Multiple Sclerosis population. J Neurol 2010;257:S75
78. Tsertsvadze A, Fink S, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009;151:650-61
79. Fowler CJ, Miller JR, Sharief MK, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:700-5 (Pubitemid 40569682)
80. Safarinejad MR Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol 2009;181:252-8
81. Lombardi G, Macchiarella A, Del Popolo G. Efficacy and safety of Tadalafil for erectile dysfunction in patients with multiple sclerosis. J Sex Med 2010;7:2192-200
82. Denil J. Ohl DA, Smythe C. Vacuum erection device in spinal cord injured men: patients and partner satisfaction. Arch Phys Rehabilit 1996;77:750-3 (Pubitemid 26262372)
83. Dasgupta R, Wiseman OJ, Kanabar G, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004;171:1189-93 (Pubitemid 38327555)
84. Kaplan SA, Reis RB, Kohn IJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999;53:481-6 (Pubitemid 29136188)
85. Caruso S, Intellisano G, Lupo L, et al. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. Br J Obstet Gynaecol 2001;108:623-8 (Pubitemid 33646504)
86. Kenner M, Menon U, Elliott DG. Multiple sclerosis as a painful disease. Int Rev Neurobiol 2007;79:303-21
87. O'Connor AB, Schwid SR, Herrmann DN, et al. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 2008;137:96-111 (Pubitemid 351794402)
88. Nurmikko TJ, Gupta S, Maclver K. Multiple sclerosis-related central pain disorders. Curr Pain Headache Rep 2010;14:189-95
89. Osterberg A, Boivie J. Central pain in multiple sclerosis-sensory abnormalities. Eur J Pain 2010;14:104-10
90. Kalia LV, O'Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler 2005;11:322-7 (Pubitemid 40775190)
91. Svendsen KB, Jensen TS, Hansen HJ, Bach FW. Sensory function and quality of life in patients with multiple sclerosis and pain. Pain 2005;114:473-81 (Pubitemid 40385885)
92. Ehde DM, Gibbons LE, Chwastiak L, et al. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler 2003;9:605-11 (Pubitemid 37479410)
93. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis: prevalence and clinical characteristics. Eur J Pain 2005;9:531-42 (Pubitemid 41222322)
94. Cruccu G, Biasiotta A, Di Rezze S, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain 2009;143:186-91
95. Solaro C, Brichetto G, Amato MP, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004;63:919-21 (Pubitemid 39297662)
96. Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology 1995;45:1294-6
97. Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol 1990;27:89-95 (Pubitemid 20031363)
98. De Simone R, Marano E, Brescia Morra V, et al. A clinical comparison of trigeminal neuralgic pain in patients with and without underlying multiple sclerosis. Neurol Sci 2005;26(Suppl 2):150-1
99. Matthews WB. Paroxysmal symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry 1975;38:617-23
100. Spissu A, Cannas A, Ferrigno P, et al. Anatomic correlates of painful tonic spasms in multiple sclerosis. Mov Disord 1999;14:331-5 (Pubitemid 30011853)
101. Restivo DA, Tinazzi M, Patti F, et al. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis, Neurology 2003;61:719-20 (Pubitemid 37082623)
102. Solaro C, Tanganelli P, Messmer Uccelli M. Pharmacological treatment of pain in multiple sclerosis. Expert Rev Neurother 2007;7:1165-74 (Pubitemid 47451023)
103. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-19 (Pubitemid 41362120)
104. Breuer B, Pappagallo M, Knotkova H, et al. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther 2007;29:2022-30 (Pubitemid 350212812)
105. Ardid D, Lamberty Y, Alloui A, et al. Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats. Eur J Pharmacol 2003;473:27-33 (Pubitemid 36851625)
106. Guay DR Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother 2003;1:18-37 (Pubitemid 40410984)
107. Rowbotham MC, Manville NS, Ren J. Pilot tolerability and effectiveness study of levetiracetam for postherpetic neuralgia. Neurology 2003;61:866-7 (Pubitemid 37174499)
108. Price MJ. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain 2004;20:33-6 (Pubitemid 38030117)
109. Enggaard TP, Klitgaard NA, Sindrup SH. Specific effect of levetiracetam in experimental human pain models. Eur J Pain 2006;10:193-8 (Pubitemid 43255205)
110. Archer DP, Lamberty Y, Wang B, et al. Levetiracetam reduces anesthetic-induced hyperalgesia in rats. Anesth Analg 2007;104:180-5 (Pubitemid 46360444)
111. Rossi S, Mataluni G, Codeca C, et al. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol 2009;16:360-6
112. Centonze D, Mori F, Koch G, et al. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci 2009;30:531-4
113. Fregni F, Freedman S, Pascual-Leone A. Recent advances in the treatment of chronic pain with non-invasive brain stimulation techniques. Lancet Neurol 2007;6:188-91 (Pubitemid 46097544)
114. Boggio PS, Zaghi S, Lopes M, Fregni F. Modulatory effects of anodal transcranial direct current stimulation on perception and pain thresholds in healthy volunteers. Eur J Neurol 2008;15:1124-30
115. Fregni F, Gimenes R, Valle AC, et al. A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. Arthritis Rheum 2006;54:3988-98 (Pubitemid 44955903)
116. Rosen AC, Ramkumar M, Nguyen T, Hoeft F. Noninvasive transcranial brain stimulation and pain. Curr Pain Headache Rep 2009;13:12-17
117. Knotkova H, Cruciani RA. Non-invasive transcranial direct current stimulation for the study and treatment of neuropathic pain. Methods Mol Biol 2010;617:505-15
118. Mori F, Codeca C, Kusayanagi H, et al. Effects of anodal transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis. J Pain 2010;11:436-42
119. Centonze D, Koch G, Versace V, et al. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. Neurology 2007;68:1045-50 (Pubitemid 46569140)
120. Mori F, Codeca C, Kusayanagi H, et al. Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. Eur J Neurol 2010;17:295-300
121. Chitsaz A, Janghorbani M, Shaygannejad V, et al. Sensory complaints of the upper extremities in multiple sclerosis: relative efficacy of nortriptyline and transcutaneous electrical nerve stimulation. Clin J Pain 2009;25:281-5
122. Solaro C, Boehmker M, Tanganelli P. Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. J Neurol 2009;256:1773-34